Physician profile
Jia Lin
NPI 1730613126
$2,328.11
in general payments reported to CMS, 2019-2025
17 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $247 · 2023: $556 · 2024: $865 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $722.59 | 2022-2025 | |
| Emd Serono, INC. | $637.75 | 2023-2025 | Mavenclad |
| Genzyme Corporation | $196.90 | 2022-2024 | |
| Abbvie INC. | $134.45 | 2023-2024 | |
| Pfizer INC. | $117.33 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $96.94 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $86.24 | 2023-2025 | |
| Amgen INC. | $74.33 | 2025 | Uplizna |
| Biogen, INC. | $69.38 | 2022-2025 | Tysabri, Vumerity |
| Hospira, INC. | $41.14 | 2024 | |
| Horizon Therapeutics Plc | $28.91 | 2022 | |
| Acadia Pharmaceuticals INC | $24.82 | 2025 | Nuplazid |
| C2n Diagnostics, LLC | $23.02 | 2025 | Precivityad2 |
| Genentech USA, INC. | $20.26 | 2024 | Ocrevus |
| Celgene Corporation | $19.80 | 2025 | Zeposia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.48 | 2023 | Emgality, Reyvow |
| Argenx US, INC. | $16.77 | 2023 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jia Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.